UNSPSC 51332804: Butaperazine

This classification denotes a dopamine antagonist with the molecular formula C24H31N3OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TXP4T9106S, chemically known as 1-butanone, 1-(10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazin-2-yl)- but generally known as butaperazine, which bears US NIH Compound Identifier 12598. Butaperazine most often comes in base and maleate forms. European Medicines Agency schedules Butaperazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06007MIG.

UNSPSC 51332804 Butaperazine is a Commodity code that nominally identifies a specific antipsychotic pharmaceutical product, but state and local procurement activity under this code does not align with that narrow scope. The three most recent opportunities posted under this code span naloxone procurement for emergency response, direct-to-manufacturer prescription program design, and multi-state cooperative purchasing of generic pharmaceuticals and OTC products—none of which are butaperazine-specific. State and local governments are buying pharmaceutical products and pharmacy program services across a much broader range than the code's name suggests, including emergency medical supplies, manufacturer-direct distribution channels, and bulk generic medication access through cooperative purchasing agreements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating states and local jurisdictions including Oregon).

Recent opportunities show geographic spread across Florida, Texas, and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response deadline July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, with no formal award timeline specified. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating jurisdictions, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. The code shows substantial recent activity, but the mismatch between the code name and actual procurement scope suggests this is a taxonomy miscoding issue rather than a reliable indicator of butaperazine demand in state and local markets.